MEDICALLY ASSISTED TREATMENT IN PROBLEMATIC OPIOID Punta Cana 2018
|
|
- Laurel McKenzie
- 5 years ago
- Views:
Transcription
1 MEDICALLY ASSISTED TREATMENT IN PROBLEMATIC OPIOID Punta Cana 2018
2 Copyright 2017 by Sea Courses Inc All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical, including photocopying, recording, or information storage and retrieval systems without prior written permission of Sea Courses Inc. except where permitted by law. Sea Courses is not responsible for any speaker or participant s statements, materials, acts or omissions.
3 CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure Faculty: JOEL BORDMAN Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Purdue, Indivior, OCFP, MedPlan, ECHO Consulting Fees: OCFP, CMPA, CNO, ONA, Purdue, Indivior, Other:
4 CFPC CoI Templates: Slide 2 Disclosure of Commercial Support This program has received financial support from SEA COURSES in the form of Honoraria. This program has received in-kind support from Sea Courses in the form of logistical support. Potential for conflict(s) of interest: Joel Bordman has received honoraria from Purdue, Indivior [Purdue, Indivior benefits from the sale of products that will be discussed in this program: Suboxone (Buprenorphine/Naloxone), OxNeo (Oxycodone LA-resistant to crushing), HydroMorphContin (Hydormorphone LA)
5 CFPC CoI Templates: Slide 3 Mitigating Potential Bias Every effort will be made to remind audience of potential bias throughout the presentation
6 OBJECTIVES To discuss treatment options in the difficult patient To review basic principles of Methadone and Buprenorphine/Naloxone. (what the non-prescriber needs to know)
7 Something to ponder A 30 year old male comes to your office asking to be your patient. He says wants to be honest with you and tells you that he is on Methadone. What is your reaction?
8 Addiction What is the easiest way to accept your patients condition? Remind yourself its a chronic disease
9 Stages of Recovery Pre-contemplative Contemplative Action Maintenance? Abstinence? Relapse
10 Treatment of Problematic Opioid Use Continue as before or increase the opioids? Immediate cessation of opioids? Rotate to another conventional opioid? Structured opioid therapy? Taper with goal of abstinence? Medically assisted treatment (MAT) with Methadone Buprenorphine/Naloxone
11 Opioid Agonist Treatment Does it work? NIH the safety & efficacy or narcotic agonist maintenance treatment have been unequivocally established. 2008: WHO Bulletin: substitution therapies such as methadone remain the most promising method of reducing drug dependence.
12 What is Opioid Maintenance Treatment? Social work advocacy & case management Stabilization of opiate receptor requirements OPIOID Maintenance Therapy Treatment Protocol Harm Reduction Counselling Source: Health Canada Best Practices 2002 Slide 12
13 Methadone maintenance reduces illicit drug use improves health status decreases transmission of HIV and Hepatitis C decreases illegal activity and incarceration increases employment decreases cost to society (cost-effective) decreases mortality
14 Using methadone: Physician needs exemption from Health Canada to legally prescribe (Exemption for use for pain obtained from Health Canada directly) Exemption for use for addiction overseen by CSPO Conditions: CAMH course, preceptorship, adherence to Guidelines, practice assessments
15 Methadone: Historical Context Invented in Germany during WWII Commercially produced for the first time by Eli- Lilly in the U.S. in 1947 Became popular in the treatment of heroin addiction in the 1960s Lost favour in the 1970s Increased interest with better understanding of pharmacology in the 1980s
16 Methadone- 3 mechanisms of action 1. mu and delta opioid receptor agonist Analgesia and typical opioid SE profile; may have more diaphoresis and flushing Lynch ME. Pain Res Manag 2005; 10(3): Davis MP.Support Cancer Care 2001; 9; Fishman SM.Pain Med 2002; 3:
17 Methadone 3 mechanisms of action 2. NMDA receptor antagonist May help to prevent or reverse opioid tolerance and hyperalgesia Theoretical advantage for neuropathic pain Lynch ME. Pain Res Manag 2005; 10(3): Davis MP.Support Cancer Care 2001; 9; Fishman SM.Pain Med 2002; 3:
18 Methadone 3 mechanisms of action 3. Inhibits re-uptake of norepinephrine & serotonin Evolving evidence for this mechanism-based analgesia via descending modulation in neuropathic pain Lynch ME. Pain Res Manag 2005; 10(3): Davis MP.Support Cancer Care 2001; 9; Fishman SM.Pain Med 2002; 3:
19 Methadone: Pharmacokinetics Administration: once per day mixed with orange juice Onset of action: Oral: 30 to 60 minutes Time to peak concentration: Oral: hours Steady state: 2-10 days (generally 3-4 days) Davis M. Support Care Cancer 2001; 9: Peng P. Can J Anesth 2005; 52: Toombs J. Amer Fam Phys 2005; 7(7):
20 Methadone Pharmacology During Initial Dosing Period (0 to 1 day) A Free fraction in plasma Drug elimination B Analgesia A B Majority of drug initially sequestered to tissue binding sites Small quantity of methadone available Gannon C. Eur J Palliative Care 1997; 4:152-8.
21 Methadone Pharmacology At Steady State (3 5 days +) C E D Analgesia C Once the reservoir is full, subsequent doses available to plasma (leading to reduced requirement) D E Increased dose fraction for analgesia In steady state equilibrium is maintained in effect a slow-release reservoir Gannon C. Eur J Palliative Care 1997; 4:152-8.
22 Methadone Drug Interactions There are 2 ways to cause an effect: 1. By starting a medication which will alter the metabolism, e.g.,: Starting fluconazole or paroxetine may reduce clearance resulting in increased serum levels and sedation/toxicity Starting retonavir or dilantin may increase clearance resulting in decreased levels and may reduce analgesia or ppt withdrawal
23 Methadone Drug Interactions 2. By stopping a medication which will alter the metabolism, e.g.,: Stopping fluconazole or paroxetine may increase clearance resulting in decreased serum levels and reduced analgesia or withdrawal symptoms Stopping retonavir or dilantin may decrease clearance resulting in increased levels and may increase analgesia or cause sedation/toxicity
24 Methadone Contraindications and Cautions (1) Caution during dose titration due to dose accumulation and variable half life Significant sleep apnea, 1 severe COPD, acute asthma or other clinically relevant states of respiratory depression Combining with alcohol or other sedating drugs, especially BZD 1. Wang D. Sleep Med Review 2007 Feb;11 (1) :
25 Methadone Contraindications and Cautions (2) Concurrent administration of any other drugs that might result in drug-drug interactions (e.g., antiretrovirals) Patients unable to comply with use instructions Prolonged QT (> 440 msec in males or 460 msec in females) 1. Wang D. Sleep Med Review 2007 Feb;11 (1) :
26 Primary care concerns for patients on Methadone Should you treat acute pain with opioids? Should you treat chronic pain with opioids? Consider screening for endocrine abnormalities (especially testosterone) Cardiac issues (QTc, endocarditis) Sleep Apnea (CENTRAL and peripheral) DRUG INTERACTIONS
27 Buprenorphine / Naloxone A more recently available long acting opioid (2008) An alternative to methadone Sublingual administration Note: you will also see buprenorphine in a transdermal preparation (lower dose, transdermal patch, approved for chronic pain)
28 Buprenorphine/Naloxone : A Confusing Combination Buprenorphine Partial mu agonist Kappa antagonist Naloxone Mu antagonist
29 HOW Buprenorphine/Naloxone WORKS Buprenorphine/Naloxone Recommended: Taken as Directed by Your Doctor Under the Tongue NOT Recommended: Misused by injecting Buprenorphine Naloxone Buprenorphine Naloxone Buprenorphine/Naloxone acts like buprenorphine alone. When Buprenorphine/Naloxone is taken under the tongue, as directed, the naloxone is silent it has no effect. Buprenorphine/Naloxone acts like naloxone. Naloxone will cause withdrawal symptoms for opioid-dependent people who have heroin or methadone (full agonists) in their bodies at the time of injection.
30 BUPRENORPHINE: A PARTIAL µ OPIOID RECEPTOR AGONIST Partial µ opioid agonist Kappa receptor antagonist Less dopamine release Heroin, oxycodone produce maximum dopamine release Buprenorphine produces less dopamine release Heroin, Oxycodone etc (Full agonist) Buprenorphine (Partial agonist) Red balls = µ opioid receptors Yellow balls = heroin Green shapes = buprenorphine Johnson RE, et al. Drug Alcohol Depend; 2003.
31 BUPRENORPHINE: A PARTIAL µ OPIOID RECEPTOR AGONIST High affinity for µ receptor Can displace full agonist opioids, such as heroin Heroin, Oxycodone etc (Full agonist) Dissociates slowly from the receptors Low intrinsic activity Ceiling on agonist effects Buprenorphine (Partial agonist) Red balls = µ opioid receptors Yellow balls = heroin Green shapes = buprenorphine Johnson RE, et al. Drug Alcohol Depend; 2003.
32 Opioid side effects Lets think of some serious side effects of opioids.. Is constipation (OIC) the most serious side effect? What about opioid induced apnea?
33 BUPRENORPHINE: A SAFE CEILING Unlike full agonists, agonist effects of buprenorphine reach a ceiling 1 Less likely to cause respiratory depression in overdose Ceiling can be compromised by concomitant alcohol or other central nervous system depressants, or when buprenorphine is misused 2 1 Johnson RE, et al. Drug Alcohol Depend; Suboxone Product Monograph.
34 PHARMACOTHERAPY PHASES IN TREATMENT Therapy divided into 4 phases Induction Stabilization Maintenance Medically supervised withdrawal
35 Induction Dosing Day 1 target Buprenorphine/Naloxone dose: 4 to 8 mg (now up to 12mg) 1 Administer 4 mg; monitor efficacy and adverse effects 2 Have patient wait for dose to take effect 1 to 2 hours after first dose Reassess the patient s withdrawal symptoms Administer another 2-4 mg depending on the individual patient s requirement 1. SUBOXONE Product Monograph. Scarborough, ON: Reckitt Benckiser Pharmaceuticals Limited, April Doran C et al. Heroin Addict Rel Clin Probl. 2005;7(1):7-18
36 Who to consider starting on a lower dose? Abstinent for a significant time Codeine users Past sensitivity to buprenorphine
37 ACTIVITY OF BUPRENORPHINE DEPENDS ON CONDITIONS AT THE MU RECEPTOR In absence of full agonist (heroin), buprenorphine binds to receptors and causes reinforcing effect Feeling normal If full agonist (heroin) is present, buprenorphine displaces agonist and causes withdrawal symptoms Wait until patient is experiencing withdrawal symptoms to avoid precipitating withdrawal Center for Substance Abuse Treatment; DHHS; 2004.
38 Buprenorphine/Naloxone Sublingual Tablets Dosing Summary >24 mg/day 16 mg/day to 24 mg/day 16 mg/day 1. SUBOXONE Product Monograph. Scarborough, ON: Reckitt Benckiser Pharmaceuticals Limited, April 2011.
39 MAINTENANCE Goals: Prevent opioid withdrawal symptoms Suppress opioid cravings Decrease the use of self-administered opioids Address the goals of rehabilitation with each patient Duration: Months to years, up to a lifetime Suboxone Product Monograph.
40 LESS THAN ONCE DAILY DOSING Buprenorphine can be dispensed every other day at twice the titrated daily dose Patient stabilized on 8 mg/day can be dispensed 16 mg every other day 1 Suboxone Product Monograph..
41 MEDICALLY SUPERVISED TAPER No scientific evidence that medical withdrawal is effective treatment Patients are at high risk for relapse during withdrawal 1,2 If the patient and physician decide to take this approach: Ensure that the patient has immediate access to maintenance treatment at all times Monitor patients on an ongoing basis for relapse 1 Kakko J, et al. Lancet; Center for Substance Abuse; DHHS, Suboxone Product Monograph
42 MAINTENANCE PROVEN MORE SUCCESSFUL THAN WITHDRAWAL No deaths 4 deaths Kakko J, et al. Lancet; 2003.
43 Buprenorphine for Maintenance vs. Methadone 1 Buprenorphine Methadone Blocks opioid effects At low doses At low doses Mechanism of action Partial opioid agonist Full opioid agonist Adverse events Precipitated withdrawal Less sedating Less risk of overdose Similar to other opioids More sedating More risk of overdose Withdrawal on cessation Less severe Severe, prolonged withdrawal Onset of action minutes minutes Peak effect 1-4 hours hours Duration of action Up to 2-3 days at high doses hours Titration More rapid titration to effect Lengthy process Mode of administration Sublingual Oral Metabolism Less clinical impact on liver function; metabolism through glucuronidation 7 All metabolism in cytochrome system; therefore more clinical impact on liver function 7 Drug interactions Fewer drug interactions 7 More drug interactions 7 46
44 Properties of a good MAT SAFETY EASE OF INITIATION EASE OF TAPER COST STIGMA
45 Safety comparison Diversion: Patients who use methadone non-medically have higher hospitalization rates, greater ICU utilization rates, and considerably worse medical outcomes when compared with patients who use buprenorphine nonmedically Benzodiazepines: non-medical use of benzodiazepines with methadone is associated with higher rates of hospitalization, greater ICU utilization rates and considerably worse medical outcomes when compared to nonmedical use of benzodiazepines with buprenorphine 1.Lee S, Medical outcomes associated with nonmedical use of methadone and buprenorphine, J Emerg Med Lee,SC et al, 2014
46 More primary care thoughts Your patient wants to taper off MAT, what would you discuss with him? Is there a role in primary care for Buprenorphine therapy? Is yes, what supports would you need? Other thoughts are welcome.
47 Thank
Building capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
More informationManagement of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013
Management of high risk MMT patients Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 CFPC CoI Templates: Slide 1 Faculty Disclosure Faculty: Meldon Kahan Relationships with commercial
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More information12/14/2018. Disclosures. Buprenorphine. Drug-Receptor Interactions. Affinity
ECHO Ontario Chronic Pain Bootcamp OPIOID CHALLENGE Buprenorphine/Naloxone: What and How? Friday, December 7, 2018 Disclosures Presenters: John Flannery & Andrew Smith Conflicts of Interest: None John
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationNow available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet
Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE
More informationMethadone Maintenance
Methadone Maintenance A Practical Guide to Pharmacotherapy Methadone/Buprenorphine 101 Workshop, April 1, 2017 Ron Joe, MD, DABAM Objectives I. Pharmacology Of Methadone II. Practical Application of Pharmacology
More informationAn overview of Medication Assisted Treatment (MAT) and acute pain management on MAT
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)
More informationOAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM
OAT Transitions - focus on microdosing Mark McLean MD MSc FRCPC CISAM DABAM Disclosures No pharmaceutical industry or other financial conflicts of interest Study Physician for research funded by Canadian
More informationOST. Pharmacology & Therapeutics. Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO
OST Pharmacology & Therapeutics Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO Disclaimer In the past two years I have received no payment for services from any agency other than government or academic.
More informationBuprenorphine pharmacology
Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely
More informationPharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
More informationDr Alistair Dunn. General Practitioner Whangarei
Dr Alistair Dunn General Practitioner Whangarei 1982 Temgesic = Buprenorphine Sublingual opiate analgesic 0.2 mg Popular drug of abuse 1991 Temgesic NX = Bup & Nalxone Nalxone added to deter abuse 1999
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationBuprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008
Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality
More informationMedications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
More informationMedication Assisted Treatment. Nicole Gastala, MD
Medication Assisted Treatment Nicole Gastala, MD Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants
More informationTreatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationOpioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine
Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene
More informationTreating Opioid Use Disorders: An Update for Counselors and Other Providers
Treating Opioid Use Disorders: An Update for Counselors and Other Providers Brad Shapiro, MD Medical Director Opiate Treatment Outpatient Program Zuckerberg San Francisco General THE DOSING WINDOW HISTORICAL
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More information2004-L SEPTEMBER
BULLETIN INTELLIGENCE Buprenorphine: Potential for Abuse Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E NDIC Within the past 2 years buprenorphine a Schedule III
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationModule Two: Pharmacotherapies for Opioid Substitution Treatment
Module Two: Pharmacotherapies for Opioid Substitution Treatment Neurobiology of Addiction Pharmacology of Opioids Methadone Buprenorphine Pharmacokinetics of Methadone & Buprenorphine Opioid effects Intoxication
More informationIndex. E Elderly. See also Older patients analgesic efficacy and opioid adverse effects, 280
A Acute pain, methadone maintained patients, 33 Addiction antisocial behaviors, 24 definition, 15 Drug Addiction Treatment Act 2000, 140 heroin, 41 morphine, 91 opioid, 16 related counseling, 23 treatment
More informationDisclosure Statement. Learning Objectives. American Psychiatric Nurses Association. Christian J. Teter, PharmD, BCPP 1 BUPRENORPHINE UPDATE
BUPRENORPHINE UPDATE Christian J. Teter, Pharm.D., BCPP Associate Professor, Psychopharmacology College Of Pharmacy, University Of New England Portland, ME E-Mail: cteter@une.edu Image Source: pubchem.ncbi.nlm.nih.gov
More informationSUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationCOMMON ADDICTIONS IN OUR Punta Cana 2018
COMMON ADDICTIONS IN OUR SOCIETY @joelbordman Punta Cana 2018 Copyright 2017 by Sea Courses Inc All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationClinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More informationQuick Guide. For Physicians. Based on TIP 40 Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Quick Guide For Physicians Based on TIP 40 Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Buprenorphine Clinical Guide Contents Why a Quick Guide?....................
More informationKnock Out Opioid Abuse in New Jersey:
Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids
More informationGOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationNational Opioid Treatment Guideline Dr. Ronald Lim
National Opioid Treatment Guideline Dr. Ronald Lim (MD, CCFP, DFASAM, ABAM(D), FISAM, CCSAM, MRO) Clinical Assistant Professor, Department of Psychiatry and Family Practice Cumming School of Medicine University
More informationImplementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018
Implementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018 Judith Martin, MD, Medical Director of Substance Use Services, San Francisco Department of Public Health Webinar
More informationOptimizing Opioid Dependence Treatment A Guideline for Pharmacists
Optimizing Opioid Dependence Treatment A Guideline for Pharmacists Module 3: Optimal Use of Methadone F e b r u a r y 2 0 1 5 Learning Objectives To know and understand the pathophysiology of substance
More informationWhat Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016
What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationTalking with your doctor
SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationChronic Pain Simplified Part 1: A Review of the 2017 Guidelines
Chronic Pain Simplified Part 1: A Review of the 2017 Guidelines Punta Cana 2018 @joelbordman Copyright 2017 by Sea Courses Inc All rights reserved. No part of this document may be reproduced, copied, stored,
More informationPrescription Opioids
What are prescription opioids? Prescription Opioids Opioids are a class of drugs naturally found in the opium poppy plant. Some prescription opioids are made from the plant directly, and others are made
More informationPrescription Opioid Addiction
CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationBrief History of Methadone Maintenance Treatment
METHADONE Brief History of Methadone Maintenance Treatment Methadone maintenance treatment was on the cusp of the social revolution in the sixties. Doctors and public health workers had concluded what
More information9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare
Buprenorphine Treatment (Suboxone) Selahattin Kurter, MD Spectrum Healthcare Board Certified in Psychiatry and Addiction Medicine Disclosures No financial reimbursement for this lecture Consultant for
More informationOptimizing Suboxone in Opioid Addicts
Optimizing Suboxone in Opioid Addicts David Chim, D.O. Integrated Substance Abuse Programs Dept. of Psychiatry, UCLA K30 Translational Research Interest March 24, 2009 dchim@mednet.ucla.edu www.uclaisap.org
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More information(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)
Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationOpiate Dependency bka Opioid Addiction
Opiate Dependency bka Opioid Addiction GP CME Dunedin July 2012 Doug Sellman Professor of Psychiatry and Addiction Medicine Director, National Addiction Centre University of Otago, Christchurch What this
More informationAnalgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015
Analgesia for Patients with Substance Abuse Disorders Lisa Jennings CN November 2015 Definitions n Addiction: A pattern of drug use characterised by aberrant drug-taking behaviours & the compulsive use
More informationSteven Prakken MD Director Medical Pain Service Duke Pain Medicine
Steven Prakken MD Director Medical Pain Service Duke Pain Medicine Misuse Abuse Addiction Total Pain Population Webster LR, Webster RM. Pain Med. 2005;6(6):432-442. DSM IV Abuse defined as 2 elements
More informationMedications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives
More informationSuboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description
More informationSlide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists
Slide 1 Opioid (Narcotic) Analgesics and Antagonists Chapter 6 1 Slide 2 Lesson 6.1 Opioid (Narcotic) Analgesics and Antagonists 1. Explain the classification, mechanism of action, and pharmacokinetics
More informationComedy of Errors: Methadone and Buprenorphine
Comedy of Errors: Methadone and Buprenorphine Douglas Gourlay MD, MSc, FRCP(C), DFASAM Disclosures Nothing to disclosure 2 1 Learning Objectives Explain the pharmacology of methadone and buprenorphine
More informationMETHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE
METHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE Work with methadone clinic staff to coordinate the methadone taper, with the transition to buprenorphine/naloxone:
More informationThe CARA & Buprenorphine Prescribing for APNs & PAs
The CARA & Buprenorphine Prescribing for APNs & PAs William J. Lorman, JD, PhD, MSN, PMHNP-BC, CARN-AP FIAAN Assistant Clinical Professor, Drexel University, Philadelphia, PA V. P. & Chief Clinical Officer,
More informationPAIN & ANALGESIA. often accompanied by clinical depression. fibromyalgia, chronic fatigue, etc. COX 1, COX 2, and COX 3 (a variant of COX 1)
Pain - subjective experience associated with detection of tissue damage ( nociception ) acute - serves as a warning chronic - nociception gone bad often accompanied by clinical depression fibromyalgia,
More informationMedication-Assisted Treatment (MAT) for Opioid Use Disorders
Medication-Assisted Treatment (MAT) for Opioid Use Disorders Sybil Marsh MA MD FASAM Department of Family Medicine and Community Health Case Western Reserve University/UHCMC Learning Objective 1 Following
More informationModule 6: Overview Opioid Dependence Treatment with Buprenorphine/Naloxone
Module 6: Overview Opioid Dependence Treatment with Buprenorphine/Naloxone History of Medical Practice for Opioid Addiction in the U.S. Physicians had been liberal prescribers of morphine in late 1800s/early
More informationMethadone Maintenance 101
Methadone Maintenance 101 OTP/DAILY DOSING CLINICS - ANDREW PUTNEY MD Conflicts of Interest - Employed by Acadia HealthCare 1 Why Methadone? At adequate doses methadone decreases opioid withdrawal symptoms
More informationThe available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs
More informationMedication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment
Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin
More informationThe Prescription Review Program and College Expectations. Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM
The Prescription Review Program and College Expectations Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM April 28, 2017 Disclosure Relationship with commercial interests: None Professional roles: Addictions
More informationOPIOID SUBSTITUTION THERAPY RISKS & BENEFITS
OPIOID SUBSTITUTION THERAPY RISKS & BENEFITS LEO O. LANOIE, MD, MPH, FCFP, CCSAM, ABAM, FISAM, MRO Dr. Leo Lanoie, 2017 DISCLAIMER In the past year I have accepted funds from Purdue for speaking OPIOID
More informationMary Ann Ferguson,Pharmacist St Josephs Health Care Concurrent Disorders Inpatient Unit
Mary Ann Ferguson,Pharmacist St Josephs Health Care Concurrent Disorders Inpatient Unit Fergusom@stjoes.ca Medication should be considered as part of the treatment plan for addictions/substance use disorders:
More information6/6/2018. Nalbuphine: Analgesic with a Niche. Mellar P Davis MD FCCP FAAHPM. Summary of Advantages. Summary of Advantages
Nalbuphine: Analgesic with a Niche Mellar P Davis MD FCCP FAAHPM 1 Summary of Advantages Safe in renal failure- fecal excretion Analgesia equal to morphine with fewer side effects Reduced constipation
More informationOpioids and Chronic Pain: Case studies and Personal Experience
Opioids and Chronic Pain: Case studies and Personal Experience Dr Rupa Patel, MD, CCFP, FCFP Assistant Professor, Department of Family Medicine, Queen s University Kingston Community Health Center Faculty/Presenter
More informationFY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
More informationDisclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.
Evolving Treads in Medication Assisted Treatment Christopher J Davis D.O. CAADC, FASAM Medical Director, The Ranch of Pennsylvania Medical Director, Pyramid Healthcare Diplomate of The American Board of
More informationBuprenorphine and MAT 101
Buprenorphine and MAT 101 Why is Medication Assisted Treatment so Important for Recovery? KEN SAFFIER, MD 7 TH ANNUAL INTEGRATION SUMMIT DECEMBER 8, 2016 Disclosures: u Ken Saffier, MD, has nothing to
More informationThe Opioid-Exposed Woman
The Opioid-Exposed Woman Management Considerations for Labor and Delivery Jane Sublette, MS, RN, CNM, WHNP-BC Fairview Ridges Hospital Objectives Describe opioid-associated risks to the mother and fetus
More informationWR Fentanyl Symposium. Opioids, Overdose, and Fentanyls
Opioids, Overdose, and Fentanyls Outline: What are opioids? Why are we experiencing and opioid crisis? Potency, purity, and product How do opioids cause overdose and overdose deaths? What is naloxone and
More informationTake Home Naloxone elearning Module Script
elearning Module Script Slide 1-3 Review the outline and the plan for the presentation. Slide 4 We do accept the cynicism of this poster. Slide 5 Read from the slide the definition of Harm Reduction Slide
More informationApproaches to Responsible Opioid Prescribing. The Opioid Naïve Patient
Approaches to Responsible Opioid Prescribing The Opioid Naïve Patient Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationMethadone Maintenance Treatment for the Opioid Dependent Patient
Methadone Maintenance Treatment for the Opioid Dependent Patient Janice F. Kauffman RN, MPH, CAS, LADC1 Assistant Professor of Psychiatry, Harvard Medical School V. P., Addiction Treatment Services, North
More informationMedication Assisted Treatment:
Medication Assisted Treatment: A Training For Multidisciplinary Addiction Professionals Module III Medications 101 Goals for Module III This module reviews the following: Overview of three medications
More informationPain, Opioids and the EMR. Dr. Gordon Schacter April 12, 2018
Pain, Opioids and the EMR Dr. Gordon Schacter April 12, 2018 Faculty/Presenter Disclosure Faculty: Gordon Schacter Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:
More informationUSE OF BUPRENORPHINE FOR CHRONIC PAIN
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences USE OF BUPRENORPHINE FOR CHRONIC PAIN MARK SULLIVAN, MD, PHD PSYCHIATRY AND BEHAVIORAL SCIENCES ANESTHESIOLOGY AND
More informationMedication Assisted Treatment
Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,
More informationPractical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR
Practical Tools to Successfully Taper Prescription Opioids Melissa Weimer, DO, MCR Objectives Understand how to calculate morphine equivalents per day Understand the steps necessary to plan a successful
More informationOpioid dependence and buprenorphine treatment
Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions
More informationProbuphine. (buprenorphine implant) New Product Slideshow
Probuphine (buprenorphine implant) New Product Slideshow Introduction Brand name: Probuphine Generic name: Buprenorphine Pharmacological class: Opioid (partial agonist-antagonist) Strength and Formulation:
More informationGuidance for the use of buprenorphine and buprenorphine with naloxone for the treatment of opioid dependence in NHS Grampian
Title: Unique Identifier: Replaces: Guidance for the use of buprenorphine and buprenorphine with naloxone for the treatment of opioid dependence in NHS Grampian NHSG/guid/bup/MGPG733 NHSG/prot/bup/MGPG518
More informationNURSING INTAKE. Provider Name: Provider Signature: Nursing Summary. Are you pregnant at this time?
NURSING INTAKE Provider Name: Provider Signature: Date: Nursing Summary Are you pregnant at this time? 3 = Don t know 4 = Tubal ligation 5 = Menopause 6 = History of hysterectomy 7 = Other: 8 = N/A patient
More informationDeveloped and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services
Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services www.randallwebber.com MAT clients are still addicted Truth: MAT clients will experience withdrawal symptoms if they stop
More informationOpioids. Sergio Hernandez, MD
Opioids Sergio Hernandez, MD Required Slide Disclosures 1. SIGNIFICANT FINANCIAL INTERESTS NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT 2. GENERAL AND OBLIGATION INTERESTS All general
More informationInterdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings
Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings BRIAN GARVEY, MD, MPH REBECCA CANTONE, MD OREGON HEALTH & SCIENCE UNIVERSITY SCAPPOOSE RURAL HEALTH CENTER Disclosures
More informationMedication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
More informationMEDICATION ASSISTED TREATMENT
MEDICATION ASSISTED TREATMENT MODULE 14 ALLIED TRADES ASSISTANCE PROGRAM PREVENTATIVE EDUCATION: SUBSTANCE USE DISORDER Medication Assisted Treatment Types of Medication Assisted Treatment: Methadone Naltrexone
More informationFENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA
FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,
More informationMAT 101: TREATMENT OF OPIOID USE DISORDER
MAT 101: TREATMENT OF OPIOID USE DISORDER WITH SPECIAL EMPHASIS ON BUPRENORPHINE/NALOXONE ICADD May 22, 2018 Alicia Carrasco, MD Debby Woodall, LCSW, ACADC Magni Hamso, MD, MPH Terry Reilly Health Services
More informationOpioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA
Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical
More information